Sage Journals: Discover world-class research

Abstract

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are enzymes recurrently mutated in various types of cancer, including glioma, cholangiocarcinoma, chondrosarcoma, and acute myeloid leukemia. Mutant IDH1/2 induce a block in differentiation and thereby contribute to the stemness and oncogenesis of their cells of origin. Recently, small-molecule inhibitors of mutant IDH1/2 have been Food and Drug Administration–approved for the treatment of IDH1/2-mutated acute myeloid leukemia. These inhibitors decrease the stemness of the targeted IDH1/2-mutated cancer cells and induce their differentiation to more mature cells. In this review, we elucidate the mechanisms by which mutant IDH1/2 induce a block in differentiation and the biological and clinical effects of the release into differentiation by mutant-IDH1/2 inhibitors. (J Histochem Cytochem 70:83–97, 2022)

Keywords

cancer stem cells chemotherapy differentiation enasidenib isocitrate dehydrogenase ivosidenib targeted therapy therapy responses 2-hydroxyglutarate

Introduction

Cancer stem-like cells (CSCs) are malignant cells with stem cell characteristics, specifically the potential for self-renewal and differentiation. Similar to stem cells in benign tissues that support the renewal of more mature cells, CSCs are hypothesized to replace malignant cells with a more limited lifespan and therefore enable the persistence of cancer in the presence or absence of cancer therapy and the metastasis of tumors. The CSC hypothesis is based on experimental models with immunodeficient mice in whom a small subset of cells from human tumors can be engrafted and populate the full diversity of malignant cells that were present in the original tumor, whereas other subsets of cancer cells do not have this ability. Although this definition of CSCs is thus largely based on the ability to engraft a tumor in an experimental mouse model and not necessarily clinical observations in human patients, the development of novel cancer therapies is increasingly impacted by the rationale that deep and durable remissions can best be achieved by targeting the CSCs and not just the tumor bulk.¹

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are enzymes that perform key roles in various cellular functions, including the regulation of carbohydrate metabolism, epigenetics, differentiation, DNA repair, and redox states. Wild-type IDH1 and IDH2 (wtIDH1/2) oxidize and decarboxylate isocitrate to α-ketoglutarate (α-KG) in the cytoplasm and mitochondria, respectively, and simultaneously reduce NADP⁺ to NADPH. Through these metabolites, wtIDH1/2 function in the aforementioned myriad of cellular processes because α-KG is a core metabolite of the tricarboxylic acid (TCA) cycle and is also necessary for the function of α-KG-dependent dioxygenases that are involved in epigenetic regulation and DNA repair.² In addition, NADPH is one of the most important sources of reducing power in most human tissues and is therefore essential in maintaining cellular redox states.^3,4 IDH1/2 mutations (IDH1/2mt) are almost always heterozygous and occur in a hotspot fashion in the enzymatically active sites, for example, IDH1^R132, IDH2^R140, and IDH2^R172, to enable a neomorphic reaction by mutant IDH1/2 (mtIDH1/2) that converts α-KG into D-2-hydroxyglutarate (D-2-HG).⁵ Human cells have a very limited capacity to metabolize D-2-HG, which subsequently accumulates to millimolar concentrations and competitively inhibits α-KG-dependent dioxygenases.^5–9 Therefore, D-2-HG is considered to be an oncometabolite. In addition, IDH1/2mt cancer cells have a decreased NADPH production capacity because mtIDH1/2 enzymes have lost the ability to reduce NADP⁺ to NADPH but instead oxidize NADPH to NADP⁺ to catalyze the conversion from α-KG to D-2-HG.^4,5,10 Together, the D-2-HG accumulation and the decreased NADPH production capacity affect the abovementioned plethora of cellular functions, which may all contribute to oncogenesis and have been extensively reviewed before.^2,9,11

IDH1/2mt are found in multiple cancer types, such as glioma and glioblastoma,^10,12,13 chondrosarcoma,¹⁴ cholangiocarcinoma,¹⁵ myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML).^16–18 In the origin of these types of cancer, IDH1/2mt are considered to be inaugural or at least early events.^14,19–22 In the case of MDS and AML, the data are conflicting because it has been postulated that IDH1/2mt are not necessarily early events in the formation of AML, but rather drive progression from precursor states such as MDS to full-blown AML.¹⁸ In tumors where IDH1/2mt are indeed inaugural or early genetic events, they are present in all, or at least the large majority of, cancer cells including the CSCs.²² As a consequence, IDH1/2mt that occur as early genetic events are important targets for cancer therapy because then all subclones contain the IDH1/2mt and are sensitive to mtIDH1/2 inhibitors. This appreciation of the contribution of IDH1/2mt to oncogenesis motivated the development of mtIDH1/2 inhibitors.²³ These small-molecule inhibitors effectively reduce the production of D-2-HG by mtIDH1/2 and are also known as sidenibs.^24,25 Examples include the mtIDH1 inhibitor ivosidenib, which is Food and Drug Administration (FDA)-approved for the treatment of IDH1mt newly diagnosed (ND), refractory or relapsed (R/R) AML and IDH1mt previously treated, locally advanced, or metastatic cholangiocarcinoma^26–29; the mtIDH2 inhibitor enasidenib, which is FDA-approved for the treatment of IDH2mt R/R AML^30,31; the dual mtIDH1/2 inhibitor vorasidenib, which is being investigated for IDH1/2mt recurrent or progressive glioma³²; and various other mtIDH1/2 inhibitors that are still in clinical trials.³³ In addition to the aforementioned indications, ivosidenib is currently being investigated for the treatment of IDH1mt glioma and chondrosarcoma in early-phase clinical trials^34,35 and enasidenib is studied in IDH2mt MDS.³⁶ Most clinical trials were conducted with mtIDH1/2 inhibitors as monotherapy, but ivosidenib and enasidenib have also been investigated in combination with intensive chemotherapy or azacitidine for AML.^37–39

IDH1/2mt in Cancer Cell Stemness and Differentiation

During the early preclinical investigation of the biological effects of mtIDH1/2 and their inhibitors, the increased stemness of IDH1/2mt cancer cells and its underlying mechanisms were already appreciated. First, several hallmarks of cellular dedifferentiation were observed when IDH1/2mt were introduced into in vitro and in vivo experimental models. Second, preclinical, translational, and clinical studies with mtIDH1/2 inhibitors consistently showed that these agents reverse this stemness and promote cellular differentiation of IDH1/2mt cancer cells. Both will be discussed in this review.

Epigenetic Hypermethylation and Cellular Dedifferentiation in mtIDH1/2 Cells

DNA and histone hypermethylation is a feature that is observed across most investigated types of cancer that frequently contain IDH1/2mt, such as glioma,⁴⁰ chondrosarcoma,^41,42 cholangiocarcinoma,²⁰ and AML.¹⁶ Furthermore, genomic hypermethylation and an associated block of differentiation are induced by the expression of mtIDH1/2 or the administration of D-2-HG in cell models related to these types of cancer, such as primary human astrocytes,^43,44 human and mouse neural stem cells,^45–47 human and mouse mesenchymal stem cells,^42,48 mouse hepatoblasts,⁴⁹ and mouse hematopoietic cells,^16,50,51 but also human embryonic cells and mouse adipocytes.⁵² These findings were associated with an increased number of IDH1/2mt cancerous stem cells when these mutations were induced in benign stem or progenitor cells of these tissues.^{16,42,44,46–50,52,53} DNA and histone hypermethylation occurs because the accumulated D-2-HG in IDH1/2mt cells inhibits α-KG-dependent demethylases, such as the DNA demethylase TET2 and the family of histone lysine demethylases (KDMs).^6,16,43,52 The need for IDH1/2mt cancer cells to induce epigenetic hypermethylation and suppress TET2 function is emphasized by the finding that in several IDH1/2mt AML patients who were successfully treated with an mtIDH1/2 inhibitor but whose AML subsequently relapsed, a novel TET2 mutation that was not present at baseline emerged and DNA hypermethylation was sustained despite low D-2-HG levels.⁵⁴ In addition to epigenetic mechanisms, IDH1/2mt also blocks differentiation via metabolic pathways. For example, mtIDH1 inhibits α-KG-dependent dioxygenases necessary for succinyl-CoA production, a critical component for heme production. The resulting succinyl-CoA deficiency attenuates heme biosynthesis in IDH1mt hematopoietic cells, blocking erythroid differentiation at the late erythroblast stage and the erythroid commitment of hematopoietic stem cells.⁵¹

Induction of Differentiation by mtIDH1/2 Inhibitors in Preclinical Models

In preclinical mechanistic studies, inhibition of mtIDH1 in primary IDH1mt glioma xenografts grown in mice induced the expression of genes associated with both astrocytic and oligodendrocytic differentiation (GFAP, AQP4, ATP1A2, PTGDS, and ZBTB16), and this effect was associated with reduced repressive H3K9 and H3K27 trimethylation on the promoters of these genes.^24,55,56 In addition, mtIDH1/2 inhibition in IDH1/2mt AML cells induces differentiation. This was observed in an IDH2mt erythroleukemia cell line, in which erythropoietin (EPO)-induced differentiation to red blood cells was restored by mtIDH2 inhibition,^25,57,58 and this was associated by the reversion of DNA and histone hypermethylation.⁵⁸ Crucially, treatment of these IDH2mt erythroleukemia cells with an mtIDH2 inhibitor did not induce apoptosis even at high dosages, suggesting that the antileukemic efficacy of mtIDH2 inhibitors is not based on cytotoxicity but on releasing the brakes on differentiation of IDH2mt AML cells that are trapped in the stem and progenitor cell compartment.⁵⁷ Similar findings were seen in primary human IDH1mt or IDH2mt AML cells in vitro and in mice xenografts, in which mtIDH1 or mtIDH2 inhibition induced blast differentiation as shown by an increase in cells that were positive for cell surface markers associated with monocytic and granulocytic differentiation (CD11b, CD14, CD15) and intracellular myeloperoxidase (MPO) as marker of maturation into the neutrophilic pathway.^25,57,59,60 Quantitatively, 20 days of mtIDH2 inhibition in primary human IDH2mt AML mouse xenografts induced differentiation of 70% of the human blood cells into the monocytic/macrophage and granulocytic lineages, which was associated with a mild to marked decrease in the percentage of human blasts (2- to 35-fold).⁵⁷ Furthermore, functional assays during mtIDH2 inhibition in primary human IDH2mt AML cells in vitro yielded the presence of mature, functional neutrophils with phagocytic activity.⁵⁷ Differentiation induction of primary human IDH1mt AML cells by mtIDH1 inhibition was associated with reduced histone trimethylation levels at the H3K4, H3K9, H3K27, and H3K36 loci, as well as reduced global DNA methylation.^59,60

However, not all epigenetic effects of IDH1/2mt are reversible. In primary IDH1mt glioma xenografts grown in mice, an mtIDH1 inhibitor induced demethylation of histone markers (see above) without appreciable changes in genome-wide DNA methylation.²⁴ Furthermore, in some preclinical glioma models, mtIDH1 inhibition had no effect on tumor growth, histone or genome-wide DNA methylation, or the expression of genes associated with stemness or glial differentiation.⁶¹ In addition, long-term studies on inducible IDH1mt in immortalized human astrocytes revealed that mtIDH1 results in progressive and sometimes irreversible accumulation of methylation marks on DNA and histones because the epigenome and transcriptome do not completely return to the original state after the subsequent long-term discontinuation of mtIDH1 expression. In agreement with these findings, mouse xenografts continuously expressing mtIDH1 exhibited a tumor growth rate that was comparable to mouse xenografts with discontinued expression of mtIDH1. On the molecular level, L1CAM, a marker for glioma stem cells, was among the genes that was persistently upregulated despite long-term loss of mtIDH1 expression, and L1CAM is associated with gliomagenesis in xenograft models.⁴⁴ In clinical studies with mtIDH1/2 inhibitors in IDH1/2mt AML patients, potent suppression of D-2-HG is sometimes observed without epigenetic demethylation. This phenomenon was associated with primary resistance against mtIDH1/2 inhibitors.⁵⁴

Induction of Differentiation by mtIDH1/2 Inhibitors in Translational Studies

In support of these preclinical findings, induction of differentiation has also been shown in patients with IDH1/2mt malignancies that were treated with mtIDH1/2 inhibitors. Translationally, the induction of differentiation has been most thoroughly studied in the context of enasidenib treatment for IDH2mt R/R AML. Direct and morphologic evidence of myeloid differentiation during enasidenib treatment was shown in a patient with IDH2^R140Q R/R AML with trisomy 8 in the majority of myeloblasts, with the persistence of trisomy 8 in promyelocytes and mature granulocytes after 4 weeks of enasidenib treatment.³¹ Of note, ivosidenib or enasidenib induces myeloid differentiation and trilineage hematopoietic recovery in IDH1/2mt R/R AML without an intercurrent period of bone marrow aplasia or hypoplasia, which is frequently seen during treatment with cytotoxic chemotherapeutic agents, consistent with differentiation as the mechanism of action.^29–31 This is corroborated by molecular data showing that in many IDH2mt R/R AML patients achieving a complete remission (CR) on enasidenib, the IDH2mt variant allelic frequencies (VAFs) were unchanged between pre-therapy leukemic cells and neutrophils at the time of CR, consistent with the differentiation of IDH2mt leukemia cells into mature neutrophils.⁶² Of note, some patients do achieve a decrease in IDH2mt VAF, and these patients have the most durable responses.³⁰ This was further confirmed by functional assays, wherein these R/R AML patients in CR on enasidenib had IDH2mt-differentiated leukemic neutrophils with intact phagocytic activity, consistent with the restoration of normal granulocyte function.⁶² In additional translational analyses in patient samples, flow cytometry–based immunophenotyping analyses revealed that enasidenib treatment promoted differentiation of not only IDH2mt cells, but also IDH2wt cells into mature cells.⁶³ The differentiation effect of enasidenib treatment on IDH2wt cells probably occurs via the abrogation of paracrine D-2-HG inhibition on differentiation of IDH2wt cells. This evidence of differentiation induction by mtIDH1/2 inhibitors can also be related to decreased DNA hypermethylation after such therapies. Genome-wide methylation is reduced in IDH1/2mt AML cells after patients have been treated with mtIDH1/2 inhibitors, but a gene expression profile associated with AML stemness persisted, suggesting that a complete reversal of the mtIDH1/2-induced DNA hypermethylation is not necessary for a clinical response.⁵⁴ In addition to these data, a longitudinal study of patients with IDH1mt cholangiocarcinoma that was treated with ivosidenib was performed. Before-treatment and on-treatment biopsies were compared, revealing that mtIDH1 inhibition induced a more differentiated morphology of cholangiocarcinoma cells on H&E staining and the expression of hepatocyte lineage markers HNF-4α, FOXA1 (HNF-3α), FOXA2 (HNF-3β), and PPARA. These signs of differentiation were associated with a better clinical response to ivosidenib and longer progression-free survival.⁶⁴ Translational data from IDH1/2mt glioma treated with mtIDH1/2 inhibitors are not available, probably due to the inherent difficulties of obtaining multiple tumor samples over time in glioma patients.

Induction of Differentiation by mtIDH1/2 Inhibitors in Patients

In addition, there is supporting evidence for the induction of differentiation by mtIDH1/2 inhibitors from the clinical characteristics of these agents in the treatment of IDH1/2mt AML. The most tangible clinical proof of this hypothesis is that ivosidenib and enasidenib can induce a differentiation syndrome in ~20% of patients with IDH1/2mt AML, which can even be fatal if left untreated. This adverse effect is called IDH-inhibitor-associated differentiation syndrome (IDH-DS) and is a boxed warning for these drugs. Patients and clinicians should therefore be alert for fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, lymphadenopathy, bone pain, and hepatic, renal, or multiorgan dysfunction. IDH-DS has many clinical similarities to the differentiation syndrome, or retinoic acid syndrome, that is observed during differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide for acute promyelocytic leukemia (APL).⁶⁵ Once IDH-DS is suspected, corticosteroid therapy and hemodynamic monitoring should be initiated until symptom resolution.^66,67

Ivosidenib and enasidenib monotherapy lead to a CR in 19–30% and to any response (CR with or without hematologic recovery, partial remission, or a morphologic leukemia-free state) in 40–55% of patients with IDH1/2mt AML, with the highest CR and response rates being achieved in ND AML and the lowest rates in R/R AML (see Table 1).^28–31 Even higher response rates have been observed when mtIDH1/2 inhibitors were combined with intensive chemotherapy or azacitidine in IDH1/2mt ND AML,^37–39 but to be able to isolate the differentiation effects of mtIDH1/2 inhibition we will focus on studies with mtIDH1/2 monotherapy. Among transfusion-dependent patients, ivosidenib and enasidenib facilitated transfusion independence for red blood cells and/or platelets in ~40% of patients.^28–30 These transfusion independence rates are considerably higher than the CR rate which supports that the mechanism of action of mtIDH1/2 inhibitors relies more on the induction of differentiation rather than cytotoxicity. This is also emphasized by the finding that more than half of the patients who had stable disease after 3 months of treatment, but who did not achieve a reduction in blast counts, reached red blood cell transfusion independence,³⁰ whereas transfusion independence is rarely reached without the achievement of a response in other therapies for AML.

Table 1.

Clinical Efficacy of mtIDH1/2 Inhibitors in Prospective Clinical Trials in Patients With IDH1/2mt Cancer.

Treatment	Patient Population	SD Rate (%)	OR Rate (%)	CR Rate (%)	Ref.
mtIDH1 inhibitors
Ivosidenib monotherapy	IDH1mt ND AML		55	30	Roboz et al.²⁸
Ivosidenib with azacitidine	IDH1mt ND AML		78	61	DiNardo et al.³⁷
Ivosidenib with 7+3	IDH1mt ND AML		87	68	Stein et al.³⁸
Ivosidenib monotherapy	IDH1mt R/R AML		42	22	DiNardo et al.²⁹
BAY1436032 monotherapy	IDH1mt AML		15	4	Heuser et al.³³
Ivosidenib monotherapy	IDH1mt cholangiocarcinoma	51	2	0	Abou-Alfa et al.²⁶
Ivosidenib monotherapy	IDH1mt glioma	67	3	0	Mellinghoff et al.³⁴
Ivosidenib monotherapy	IDH1mt chondrosarcoma	52	0	0	Tap et al.³⁵
mtIDH2 inhibitor
Enasidenib with azacitidine	IDH2mt ND AML		74	54	DiNardo et al.³⁹
Enasidenib with 7+3	IDH2mt ND AML		87	55	Stein et al.³⁸
Enasidenib monotherapy	IDH2mt R/R AML		40	19	Stein et al.³⁰
Enasidenib monotherapy	IDH2mt MDS		53	0	Stein et al.³⁶
Vorasidenib monotherapy	IDH1/2mt glioma	73	18	0	Mellinghoff et al.³²
Other agents
Azacitidine with venetoclax	IDH1/2mt ND AML, ineligible for 7+3			75	DiNardo et al.⁶⁸
Venetoclax with HMA	IDH1/2mt ND AML, ineligible for 7+3			86	Pollyea et al.⁶⁹
Venetoclax with HMA/LDAC	IDH1mt ND AML, ineligible for 7+3			82	DiNardo et al.⁷⁰
Venetoclax with HMA/LDAC	IDH2mt ND AML, ineligible for 7+3			100	DiNardo et al.⁷⁰
Venetoclax with LDAC	IDH1/2mt ND AML, ineligible for 7+3			57	Wei et al.⁷¹
Venetoclax monotherapy	IDH1/2mt R/R AML		50	33	Konopleva et al.⁷²

Abbreviations: SD, stable disease; OR, overall response; CR, complete remission (for hematologic malignancies) or complete response (for solid tumors); ND, newly diagnosed; AML, acute myeloid leukemia; 7+3, intensive chemotherapy with 7 days of cytarabine and 3 days of an anthracycline; R/R, relapsed or refractory; MDS, myelodysplastic syndromes; HMA, hypomethylating agent/DNA methyltransferase inhibitor, that is, azacitidine or decitabine; LDAC, low-dose cytarabine.

In addition, the median time to first response (~2 months) and the median time to best response (~3–4 months) of ivosidenib and enasidenib are more similar to the response patterns of hypomethylating therapy with decitabine, azacitidine, or low-dose cytarabine than with intensive chemotherapy.^{29–31,39,73,74} This similarity may be relevant because at low doses, hypomethylation agents also mainly work via the induction of differentiation and only limitedly via cytotoxic effects and can require 4–6 months to induce a response.⁷⁴ Furthermore, IDH1/2mt VAFs were studied before and during treatment with mtIDH1/2 inhibitors. Responses to mtIDH1/2 inhibitors were observed in patients with clonal IDH1/2mt and patients with subclonal IDH1/2mt, suggesting that ancestral or non-ancestral IDH1/2mt clones are both amenable to respond to mtIDH1/2 inhibitors.^33,62,75 This is relevant because in ancestral IDH1/2mt clones the IDH1/2mt is likely present in the CSC compartment, whereas in non-ancestral IDH1/2mt clones the IDH1/2mt may not be present in the CSC compartment.¹⁸ Ivosidenib and enasidenib induced an IDH1/2mt molecular remission, defined as an IDH1/2mt VAF below the limit of detection (0.02–0.04%), in ~10–30% of patients, and all of them had a hematologic response, often a CR (~80–100%).^28–30 As expected, patients with an IDH1/2mt molecular remission were more likely to achieve a CR and a significantly longer overall survival than patients without a molecular remission (15 months vs 10 months for ivosidenib and 23 months vs 9 months for enasidenib), suggesting that IDH1/2mt clearance from all AML cells, including the CSC compartment, is necessary for a deep and durable remission.^29,30,54

With respect to the pharmacodynamics of mtIDH1/2 inhibitors, variable efficacies with respect to plasma D-2-HG level reductions have been described, but the relationship is unclear between the extent of the decrease in plasma D-2-HG levels and the likelihood of a clinical response. For example, ivosidenib generally achieves a near-complete suppression of plasma D-2-HG levels in IDH1mt R/R AML patients, but many patients with such near-complete D-2-HG reductions do not respond to ivosidenib. More specifically, plasma D-2-HG was reduced by a median of 95% in patients who achieved a response and an almost equal median of 94% in those who did not achieve a response.²⁹ On the contrary, this disconcordance between suppression of plasma D-2-HG levels and clinical benefit might be disease-specific to AML because in cholangiocarcinoma, treatment duration, which may be a surrogate for clinical efficacy, appeared to be associated with suppressed plasma D-2-HG levels after one cycle of ivosidenib treatment.²⁷ In the context of enasidenib, a more potent reduction of plasma D-2-HG levels was achieved in IDH2^R140Q than in IDH2^R172K R/R AML patients (median −93% vs median −47%).^30,31 In patients with IDH2^R140Q R/R AML, the level of plasma D-2-HG reduction by enasidenib was not associated with a clinical response, with plasma D-2-HG reductions of −94%, −95%, and −90% in patients with a CR, non-CR response, or no response, respectively. In contrast, plasma D-2-HG suppression by enasidenib was associated with the clinical response in IDH2^R172K R/R AML patients, with plasma D-2-HG reductions of −82%, −44%, and −38% in the abovementioned categories, respectively.³⁰ These D-2-HG reductions are not complete, not even in patients achieving a CR, because of background D-2-HG production in non-malignant cells by other enzymes than mtIDH1/2. In addition, these data show that near-complete abrogation of D-2-HG production by IDH2mt AML cells is not always sufficient to induce a CR. This suggests that IDH1/2mt AML can develop resistance mechanisms that confer D-2-HG independence or that D-2-HG production is not homogeneously stopped in all malignant cells within IDH1/2mt AML with residual D-2-HG production still occurring in the CSC compartment.

Resistance Mechanisms to mtIDH1/2 Inhibitors

Several mechanisms of primary and secondary resistance to mtIDH1/2 inhibitors have been described. In primary resistance, a patient fails to respond to a therapy. In secondary resistance, relapse occurs after an earlier response to a therapy. In both cases, the CSC compartment may play a crucial role.

With respect to primary resistance to mtIDH1/2 inhibitors, an universal mechanism across various types of IDH1/2mt cancers has not yet been described. In IDH1/2mt AML, baseline co-mutations in genes of the receptor tyrosine kinase (RTK) pathway (NRAS, FLT3, and PTPN11) and hematopoietic differentiation transcription factors (RUNX1, CEBPA, and GATA2) are negatively associated with the occurrence of a response to mtIDH1/2 inhibitors.^30,62,75 These findings can be partially extended to IDH1/2mt cholangiocarcinoma, in which gene signatures associated with activated RTK and PI3K/AKT-activity are associated with early progression upon treatment with ivosidenib.⁶⁴ In glioma, the presence of genetic alterations in cell cycle pathway genes was associated with a shorter progression-free survival.³⁴ In addition to these genetic hallmarks of mtIDH1/2-inhibitor primary resistance, leukemia stemness is associated with poor responses to mtIDH1/2 inhibitors in IDH1/2mt AML. In primary samples of patients with IDH1/2mt AML treated with mtIDH1/2 inhibitors, resistance to mtIDH1/2 inhibitors was more frequently observed in patients with versus patients without a hypermethylated genotype with a gene expression profile associated with AML stemness. In addition, a genetic CSC risk score, the LSC17,⁷⁶ was a better predictor for response to mtIDH1/2 inhibition than the established and aforementioned molecular risk factors such as cytogenetics, RUNX1 mutation status, or RAS/RTK mutation status.⁵⁴

With respect to secondary resistance to mtIDH1/2 inhibitors, several mechanisms have been described, and they may be more universal across the various types of IDH1/2mt cancers. First, there is the emergence of downstream mutations, such as TET2, BCOR, differentiation genes (RUNX1, GATA2, CEPBA), and RTK genes (RAS, FLT3, PTPN11, KIT).^54,63,75,77 Second, IDH1/2mt patients who relapse on mtIDH1/2 inhibitor therapy may do so because of D-2-HG-restoring mutations.^{54,63,75,78,79} Restoration of D-2-HG production during mtIDH1 or mtIDH2 inhibition can result either from a second-site mutation in the inhibited IDH1/2 homolog that prevents binding of the mtIDH1/2 inhibitor or from a process termed isoform switching or homolog switching, in which an IDH2mt emerges during mtIDH1 inhibition or vice versa.^{54,63,75,78,79} In patients with IDH1mt R/R AML, 35% of patients who achieved a response on enasidenib developed such a D-2-HG-restoring mutation, with second-site mutations and homolog switching occurring in equal proportions of patients (~20%). Second-site mutations, such as IDH1^S280F, IDH1^R119P, IDH2^Q316E, and IDH2^I319M,^54,75,78 occur outside of the catalytically active site of the IDH1/2 enzymes and are modeled to directly or indirectly prevent the binding of allosteric mtIDH1/2 inhibitors such as ivosidenib and enasidenib.⁷⁵ Among relapsing IDH1mt R/R AML patients who exhibited isoform switching, most developed an IDH2mt that was not yet detected at baseline, either in the same clone that was previously IDH1mt or in a separate clone.⁷⁵ A smaller proportion of patients had two co-existing clones, one IDH1mt and one IDH2mt, with the relapse driven by the IDH2mt clone during mtIDH1 inhibition.⁷⁵ A final mechanism of acquired mtIDH1 inhibitor resistance was described in IDH1mt cholangiocarcinoma in which an IDH1^R132C mutation converted to an IDH1^R132F mutation, suggesting that the phenylalanine instead of the cysteine at residue 132 confers resistance to ivosidenib.⁷⁷

Currently, second-generation mtIDH1/2 inhibitors are in development, which may decrease the secondary resistance rates to mtIDH1/2 inhibition. Vorasidenib inhibits both mtIDH1 and mtIDH2 at nanomolar concentrations⁸⁰ and is currently under investigation for IDH1/2mt glioma.³² Its dual mtIDH1/2 inhibition will likely reduce the possibility for IDH1/2mt cells to escape mtIDH1/2 inhibition via isoform switching. In addition, a novel type of inhibitor that is in preclinical testing does not target the allosteric site, but instead binds the active site of mtIDH1,⁸¹ thereby decreasing the possibility for IDH1/2mt to restore their D-2-HG production via a second-site mutation at the allosteric site.

Combination Therapies With mtIDH1/2 Inhibitors

Another therapeutic strategy that may increase the clinical benefit of mtIDH1/2 inhibitors or decrease the risk of resistance is combining these drugs with other anti-cancer agents. For example, ivosidenib and enasidenib have been combined with intensive chemotherapy or azacitidine in IDH1/2mt ND AML,^37–39 and these strategies achieved higher response rates than ivosidenib or enasidenib monotherapy (see Table 1). This supports the notion that the best clinical outcomes in patients with IDH1/2mt cancer may be achieved by a combination of an mtIDH1/2 inhibitor with another targeted agent or chemotherapy.^37–39 Although preclinical evidence suggested that mtIDH1/2 inhibitors decrease the effect of cytotoxic therapy in IDH1/2mt cancer cells,^82–84 impressive response rates have been achieved with ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with IDH1/2mt ND AML.³⁸ However, this study was not randomized and thus cannot confirm or contradict the aforementioned preclinical warnings against combining mtIDH1/2 inhibitors with cytotoxic therapy. Whether or not adding mtIDH1/2 inhibitors to intensive chemotherapy has clinical benefit in patients with IDH1/2mt ND AML is currently being studied in a randomized clinical trial.³⁸

Combining azacitidine and enasidenib in vitro results in greater reductions in DNA methylation and enhanced EPO-induced erythroid differentiation in an erythroleukemia cell line overexpressing mtIDH2, compared with azacitidine or enasidenib alone. This is consistent with a model wherein enasidenib-induced reactivation of TET DNA demethylase enzymes contributes to azacitidine-induced inhibition of DNA methyltransferase enzymes.⁸⁵ In agreement with these preclinical results, a high CR rate of 61% was achieved with ivosidenib plus azacitidine in patients with IDH1mt ND AML ineligible for intensive chemotherapy in a non-randomized clinical trial.³⁷ Moreover, in a randomized clinical trial, the CR rate was significantly higher in the enasidenib plus azacitidine group compared with the azacitidine-only group (54% vs 12%).³⁹

Another potential powerful combination is that of an mtIDH1/2 inhibitor and the BCL2 inhibitor venetoclax. IDH1/2mt cancers are sensitive to BCL2 inhibition because D-2-HG accumulation induces BCL2 dependence via inhibition of cytochrome c oxidase, also known as complex IV of the electron transport chain. This effect lowered the threshold to trigger mitochondrial apoptosis upon BCL2 inhibition by venetoclax and rendered IDH1/2mt AML cells 13-fold more sensitive to venetoclax compared with IDH1/2wt AML cells.⁸⁶ This observation is corroborated by clinical data, in which venetoclax achieved a modest 33% CR rate when administered as monotherapy to IDH1/2mt R/R AML patients,⁷² but high and durable CR rates (57–100%) when administered in combination with azacitidine, decitabine, or low-dose cytarabine in patients with IDH1/2mt ND AML who were ineligible for intensive chemotherapy (see Table 1).^68–71 However, the finding that D-2-HG increases BCL2 dependency may also impose a limitation on combining mtIDH1/2 inhibitors and venetoclax. Suppression of D-2-HG production by an mtIDH1/2 inhibitor may decrease the BCL2 dependency of IDH1/2mt cancer cells and instead facilitate resistance against venetoclax. On the contrary, mtIDH1/2 inhibitor-induced differentiation may further increase venetoclax activity on IDH1/2mt cells by lowering the apoptotic threshold, as has been observed with other agents that promote differentiation.⁸⁷ In vitro and in vivo experiments with an erythroleukemia cell line and primary AML samples suggested that enasidenib-induced differentiation further sensitizes IDH2mt AML cells to venetoclax, but that venetoclax might be antagonized by enasidenib when it fails to induce differentiation when administered as enasidenib monotherapy. A conundrum here is that in all three primary AML samples studied as mouse xenografts, the combination of enasidenib and venetoclax induced more differentiation as measured by CD15 expression than enasidenib monotherapy alone, even when enasidenib seemed to antagonize the antiproliferative effect of venetoclax.⁸⁷ Clinical trials on the combination of an mtIDH1/2 inhibitor and venetoclax are currently ongoing.

Other Differentiation Strategies Directly or Indirectly Targeting mtIDH1/2

In addition to mtIDH1/2 inhibitors, other differentiation agents may be used to induce differentiation of IDH1/2mt AML cells. For example, IDH1/2mt induces H3K4 trimethylation of the CEBPA promoter and thereby increases the expression of this transcription factor in AML cells. In the context of normal hematopoiesis and AML, CEBPα expression is associated with the granulocyte-monocytic progenitor step and IDH1/2mt AML cells are therefore locked in this stage. This block in differentiation was associated with a gene expression signature that was enriched for genes responsive to treatment with ATRA, analogous to promyelocytic leukemia/retinoic acid receptor α (PML/RARα)-driven APL. This was supported by experiments in primary IDH1/2mt AML mouse xenografts, in which ATRA-induced differentiation of AML blasts to more differentiated granulomonocytic cells was achieved in a similar fashion as APL, but not primary IDH1/2wt AML xenografts.⁸⁸

As mentioned above, mtIDH1/2 inhibitors can induce transfusion independence for red blood cells and/or platelets in IDH1/2mt AML patients.^28–30 An interesting observation is that enasidenib can also induce hematopoietic differentiation independently of wtIDH2 or mtIDH2. In IDH2-deficient hematopoietic-progenitor cells, enasidenib but no other mtIDH1/2 inhibitors induced differentiation to mature erythrocytes. This process was mediated by accumulation of protoporphyrin IX, the direct precursor of heme, by virtue of off-target inhibition of enasidenib on the ATP-binding cassette subfamily G member 2 (ABCG2), a transporter highly expressed in erythroid progenitors which is responsible for efflux of protoporphyrin IX. Therefore, enasidenib may be a promising therapeutic agent for improvement of anemia in a wide array of clinical contexts outside of IDH1/2mt cancers.⁸⁹ This mechanism is supplementary to the mtIDH1/2-inhibitor-induced restoration of the abovementioned deficiency of succinyl-CoA in IDH1/2mt myeloid progenitor cells, a critical component for heme biosynthesis.⁵¹

Concluding Remarks and Future Perspectives

IDH1/2mt are attractive therapeutic targets for various reasons, but most prominently because they are early events in oncogenesis and are therefore present in a large proportion of cancer cells, including the CSC compartment. These mutations induce a block in differentiation early in the maturation of cells in glial, cartilaginous, biliary, and myeloid tissues, and mtIDH1/2 inhibitors potently reverse the metabolic effects of mtIDH1/2 and release differentiation of IDH1/2mt cells into more mature cells. Because the mechanism of action is different and/or complementary to that of cytotoxic agents, other hypomethylating agents and other targeted agents such as venetoclax, we envisage that mtIDH1/2 inhibitors can be most efficaciously used in combination with these agents and that multiple classes of drugs can collaborate in the optimal eradication of the CSC compartment and, therefore, long-term remissions for IDH1/2mt cancer patients.

Footnotes

Competing interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author Contributions

RJM wrote the first draft, and JWW supervised the writing. Both authors have read and approved the manuscript prior to submission.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Dutch Cancer Society (KWF; grant 10460) and the Fondation pour la Recherche Nuovo-Soldati (2019).

References

Rosen

Jordan

CT.

The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670–3. doi:10.1126/science.1171837.

Molenaar

Radivoyevitch

Maciejewski

van Noorden

Bleeker

FE.

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta. 2014 Dec;1846(2):326–41. doi:10.1016/j.bbcan.2014.05.004.

Atai

Renkema-Mills

Bosman

Schmidt

Rijkeboer

Tigchelaar

Bosch

Troost

Jonker

Bleeker

Miletic

Bjerkvig

De Witt Hamer

Van Noorden

CJ.

Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem. 2011 May;59(5):489–503. doi:10.1369/0022155411400606.

Bleeker

Atai

Lamba

Jonker

Rijkeboer

Bosch

Tigchelaar

Troost

Vandertop

Bardelli

Van Noorden

CJ.

The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010 Apr;119(4):487–94. doi:10.1007/s00401-010-0645-6.

Dang

White

Gross

Bennett

Bittinger

Driggers

Fantin

Jang

Jin

Keenan

Marks

Prins

Ward

Yen

Liau

Rabinowitz

Cantley

Thompson

Vander Heiden

SM.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10;462(7274):739–44. doi:10.1038/nature08617.

Yang

Liu

Yang

Wang

Kim

Ito

Yang

Wang

Xiao

Liu

Jiang

Liu

Zhang

Wang

Frye

Zhang

Lei

Guan

Zhao

Xiong

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011 Jan 18;19(1):17–30. doi:10.1016/j.ccr.2010.12.014.

Koivunen

Lee

Duncan

Lopez

Ramkissoon

Losman

Joensuu

Bergmann

Gross

Travins

Weiss

Looper

Ligon

Verhaak

Yan

Kaelin

Jr.

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15;483(7390):484–8. doi:10.1038/nature10898.

Chowdhury

Yeoh

Tian

Hillringhaus

Bagg

Rose

Leung

Woon

Yang

McDonough

King

Clifton

Klose

Claridge

Ratcliffe

Schofield

Kawamura

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011 May;12(5):463–9. doi:10.1038/embor.2011.43.

Losman

Koivunen

Kaelin

Jr.

2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer. 2020 Dec;20(12):710–26. doi:10.1038/s41568-020-00303-3.

10.

Yan

Parsons

Jin

McLendon

Rasheed

Yuan

Kos

Batinic-Haberle

Jones

Riggins

Friedman

Reardon

Herndon

Kinzler

Velculescu

Vogelstein

Bigner

DD.

IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765–73. doi:10.1056/NEJMoa0808710.

11.

Pirozzi

Yan

The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021 Jun 15;18:645–61. doi:10.1038/s41571-021-00521-0.

12.

Parsons

Jones

Zhang

Lin

Leary

Angenendt

Mankoo

Carter

Siu

Gallia

Olivi

McLendon

Rasheed

Keir

Nikolskaya

Nikolsky

Busam

Tekleab

Diaz

Jr Hartigan

Smith

Strausberg

Marie

Shinjo

Yan

Riggins

Bigner

Karchin

Papadopoulos

Parmigiani

Vogelstein

Velculescu

Kinzler

KW.

An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807–12. doi:10.1126/science.1164382.

13.

Molenaar

Verbaan

Lamba

Zanon

Jeuken

Boots-Sprenger

Wesseling

Hulsebos

Troost

van Tilborg

Leenstra

Vandertop

Bardelli

van Noorden

Bleeker

FE.

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014 Sep;16(9):1263–73. doi:10.1093/neuonc/nou005.

14.

Pansuriya

van Eijk

d’Adamo

van Ruler

Kuijjer

Oosting

Cleton-Jansen

van Oosterwijk

Verbeke

Meijer

van Wezel

Nord

Sangiorgi

Toker

Liegl-Atzwanger

San-Julian

Sciot

Limaye

Kindblom

Daugaard

Godfraind

Boon

Vikkula

Kurek

Szuhai

French

Bovee

JV.

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome

Nat Genet. 2011 Nov 06;43(12):1256–61. doi:10.1038/ng.1004.

15.

Borger

Tanabe

Fan

Lopez

Fantin

Straley

Schenkein

Hezel

Ancukiewicz

Liebman

Kwak

Clark

Ryan

Deshpande

Dias-Santagata

Ellisen

Zhu

Iafrate

AJ.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9. doi:10.1634/theoncologist.2011-0386.

16.

Figueroa

Abdel-Wahab

Ward

Patel

Shih

Bhagwat

Vasanthakumar

Fernandez

Tallman

Sun

Wolniak

Peeters

Liu

Choe

Fantin

Paietta

Lowenberg

Licht

Godley

Delwel

Valk

Thompson

Levine

Melnick

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14;18(6):553–67. doi:10.1016/j.ccr.2010.11.015.

17.

Mardis

Ding

Dooling

Larson

McLellan

Chen

Koboldt

Fulton

Delehaunty

McGrath

Fulton

Locke

Magrini

Abbott

Vickery

Reed

Robinson

Wylie

Smith

Carmichael

Eldred

Harris

Walker

Peck

Dukes

Sanderson

Brummett

Clark

McMichael

Meyer

Schindler

Pohl

Wallis

Shi

Lin

Schmidt

Tang

Haipek

Wiechert

Ivy

Kalicki

Elliott

Ries

Payton

Westervelt

Tomasson

Watson

Baty

Heath

Shannon

Nagarajan

Link

Walter

Graubert

DiPersio

Wilson

Ley

TJ.

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009 Sep 10;361(11):1058–66. doi:10.1056/NEJMoa0903840.

18.

Molenaar

Thota

Nagata

Patel

Clemente

Przychodzen

Hirsh

Viny

Hosano

Bleeker

Meggendorfer

Alpermann

Shiraishi

Chiba

Tanaka

van Noorden

Radivoyevitch

Carraway

Makishima

Miyano

Sekeres

Ogawa

Haferlach

Maciejewski

JP.

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015 Nov;29(11):2134–42. doi:10.1038/leu.2015.91.

19.

Schumacher

Bunse

Pusch

Sahm

Wiestler

Quandt

Menn

Osswald

Oezen

Ott

Keil

Balss

Rauschenbach

Grabowska

Vogler

Diekmann

Trautwein

Eichmuller

Okun

Stevanovic

Riemer

Sahin

Friese

Beckhove

von Deimling

Wick

Platten

A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Aug 21;512(7514):324–7. doi:10.1038/nature13387.

20.

Farshidfar

Zheng

Gingras

Newton

Shih

Robertson

Hinoue

Hoadley

Gibb

Roszik

Covington

Shinbrot

Stransky

Hegde

Yang

Reznik

Sadeghi

Pedamallu

Ojesina

Hess

Auman

Rhie

Bowlby

Borad

Cancer Genome Atlas

Zhu

Stuart

Sander

Akbani

Cherniack

Deshpande

Mounajjed

Foo

Torbenson

Kleiner

Laird

Wheeler

McRee

Bathe

Andersen

Bardeesy

Roberts

Kwong

LN.

Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017 Mar 14;18(11):2780–94. doi:10.1016/j.celrep.2017.02.033.

21.

Papaemmanuil

Gerstung

Bullinger

Gaidzik

Paschka

Roberts

Potter

Heuser

Thol

Bolli

Gundem

Van Loo

Martincorena

Ganly

Mudie

McLaren

O’Meara

Raine

Jones

Teague

Butler

Greaves

Ganser

Dohner

Schlenk

Dohner

Campbell

PJ.

Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 Jun 9;374(23):2209–21. doi:10.1056/NEJMoa1516192.

22.

Venteicher

Tirosh

Hebert

Yizhak

Neftel

Filbin

Hovestadt

Escalante

Shaw

Rodman

Gillespie

Dionne

Luo

Ravichandran

Mylvaganam

Mount

Onozato

Nahed

Wakimoto

Curry

Iafrate

Rivera

Frosch

Golub

Brastianos

Getz

Patel

Monje

Cahill

Rozenblatt-Rosen

Louis

Bernstein

Regev

Suva

ML.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 Mar 31;355(6332):eaai8478. doi:10.1126/science.aai8478.

23.

Popovici-Muller

Saunders

Salituro

Travins

Yan

Zhao

Gross

Dang

Yen

Yang

Straley

Jin

Kunii

Fantin

Zhang

Pan

Shi

Biller

SM.

Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett. 2012 Oct 11;3(10):850–5. doi:10.1021/ml300225h.

24.

Rohle

Popovici-Muller

Palaskas

Turcan

Grommes

Campos

Tsoi

Clark

Oldrini

Komisopoulou

Kunii

Pedraza

Schalm

Silverman

Miller

Wang

Yang

Chen

Kernytsky

Rosenblum

Liu

Biller

Brennan

Chan

Graeber

Yen

Mellinghoff

IK.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626–30. doi:10.1126/science.1236062.

25.

Wang

Travins

DeLaBarre

Penard-Lacronique

Schalm

Hansen

Straley

Kernytsky

Liu

Gliser

Yang

Gross

Artin

Saada

Mylonas

Quivoron

Popovici-Muller

Saunders

Salituro

Yan

Murray

Wei

Gao

Dang

Dorsch

Agresta

Schenkein

Biller

de Botton

Yen

KE.

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013 May 3;340(6132):622–6. doi:10.1126/science.1234769.

26.

Abou-Alfa

Macarulla

Javle

Kelley

Lubner

Adeva

Cleary

Catenacci

Borad

Bridgewater

Harris

Murphy

Whisenant

Lowery

Goyal

Shroff

El-Khoueiry

Fan

Chamberlain

Jiang

Gliser

Pandya

Valle

Zhu

AX.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796–807. doi:10.1016/S1470-2045(20)30157-1.

27.

Zhu

Macarulla

Javle

Kelley

Lubner

Adeva

Cleary

Catenacci

DVT

Borad

Bridgewater

Harris

Murphy

Whisenant

Lowery

Goyal

Shroff

El-Khoueiry

Chamberlain

Aguado-Fraile

Choe

Liu

Gliser

Pandya

Valle

Abou-Alfa

GK.

Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021 Sep 23. doi:10.1001/jamaoncol.2021.3836.

28.

Roboz

DiNardo

Stein

de Botton

Mims

Prince

Altman

Arellano

Donnellan

Erba

Mannis

Pollyea

Stein

Watts

Fathi

Kantarjian

Tallman

Choe

Dai

Fan

Wang

Zhang

Yen

Kapsalis

Hickman

Liu

Agresta

Attar

Stone

RM.

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463–71. doi:10.1182/blood.2019002140.

29.

DiNardo

Stein

de Botton

Roboz

Altman

Mims

Swords

Collins

Mannis

Pollyea

Donnellan

Fathi

Pigneux

Erba

Prince

Stein

Foran

Traer

Stuart

Arellano

Slack

Sekeres

Willekens

Choe

Wang

Zhang

Yen

Kapsalis

Yang

Dai

Fan

Goldwasser

Liu

Agresta

Attar

Tallman

Stone

Kantarjian

HM.

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386–98. doi:10.1056/NEJMoa1716984.

30.

Stein

DiNardo

Fathi

Pollyea

Stone

Altman

Roboz

Patel

Collins

Flinn

Sekeres

Stein

Kantarjian

Levine

Vyas

MacBeth

Tosolini

VanOostendorp

Gupta

Lila

Risueno

Yen

Attar

Tallman

de Botton

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 Feb 14;133(7):676–87. doi:10.1182/blood-2018-08-869008.

31.

Stein

DiNardo

Pollyea

Fathi

Roboz

Altman

Stone

DeAngelo

Levine

Flinn

Kantarjian

Collins

Patel

Frankel

Stein

Sekeres

Swords

Medeiros

Willekens

Vyas

Tosolini

Knight

Yen

Agresta

de Botton

Tallman

MS.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722–31. doi:10.1182/blood-2017-04-779405.

32.

Mellinghoff

Penas-Prado

Peters

Burris

III Maher

Janku

Cote

de la Fuente

Clarke

Ellingson

Chun

Young

Liu

Choe

Hassan

Steelman

Pandya

Cloughesy

Wen

PY.

Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res. 2021 Aug 15;27(16):4491–9. doi:10.1158/1078-0432.CCR-21-0611.

33.

Heuser

Palmisiano

Mantzaris

Mims

DiNardo

Silverman

Wang

Fiedler

Baldus

Schwind

Pardee

Perl

Cai

Kaulfuss

Lagkadinou

Rentzsch

Wagner

Wilkinson

Jeffers

Genvresse

Kramer

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia. 2020 Nov;34(11):2903–13. doi:10.1038/s41375-020-0996-5.

34.

Mellinghoff

Ellingson

Touat

Maher

De La Fuente

Holdhoff

Cote

Burris

Janku

Young

Huang

Jiang

Choe

Fan

Yen

Bowden

Steelman

Pandya

Cloughesy

Wen

PY.

Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020 Oct 10;38(29):3398–406. doi:10.1200/JCO.19.03327.

35.

Tap

Villalobos

Cote

Burris

Janku

Mir

Beeram

Wagner

Jiang

Choe

Yen

Gliser

Fan

Agresta

Pandya

Trent

JC.

Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma. J Clin Oncol. 2020 May 20;38(15):1693–701. doi:10.1200/JCO.19.02492.

36.

Stein

Fathi

DiNardo

Pollyea

Roboz

Collins

Sekeres

Stone

Attar

Frattini

Tosolini

See

MacBeth

de Botton

Tallman

Kantarjian

HM.

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr;7(4):e309–19. doi:10.1016/S2352-3026(19)30284-4.

37.

DiNardo

Stein

Fathi

Frankfurt

Schuh

Dohner

Martinelli

Patel

Raffoux

Tan

Zeidan

de Botton

Kantarjian

Stone

Frattini

Lersch

Gong

Gianolio

Zhang

Franovic

Fan

Goldwasser

Daigle

Choe

Winkler

Vyas

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2021 Jan 1;39(1):57–65. doi:10.1200/JCO.20.01632.

38.

Stein

DiNardo

Fathi

Mims

Pratz

Savona

Stein

Stone

Winer

Seet

Dohner

Pollyea

McCloskey

Odenike

Lowenberg

Ossenkoppele

Patel

Roshal

Frattini

Lersch

Franovic

Nabhan

Fan

Choe

Wang

Hua

Almon

Cooper

Kantarjian

Tallman

MS.

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 Apr 1;137(13):1792–803. doi:10.1182/blood.2020007233.

39.

DiNardo

Schuh

Stein

Montesinos

Wei

de Botton

Zeidan

Fathi

Kantarjian

Bennett

Frattini

Martin-Regueira

Lersch

Gong

Hasan

Vyas

Dohner

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 Nov;22(11):1597–608. doi:10.1016/S1470-2045(21)00494-0.

40.

Noushmehr

Weisenberger

Diefes

Phillips

Pujara

Berman

Pan

Pelloski

Sulman

Bhat

Verhaak

Hoadley

Hayes

Perou

Schmidt

Ding

Wilson

Van Den Berg

Shen

Bengtsson

Neuvial

Cope

Buckley

Herman

Baylin

Laird

Aldape

, Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510–22. doi:10.1016/j.ccr.2010.03.017.

41.

Nicolle

Ayadi

Gomez-Brouchet

Armenoult

Banneau

Elarouci

Tallegas

Decouvelaere

Aubert

Redini

Marie

Labit-Bouvier

Reina

Karanian

le Nail

Anract

Gouin

Larousserie

de Reynies

de Pinieux

Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nat Commun. 2019 Oct 11;10(1):4622. doi:10.1038/s41467-019-12525-7.

42.

Venneti

Akalin

Fang

Ward

Dematteo

Intlekofer

Chen

Hameed

Nafa

Agaram

Cross

Khanin

Mason

Healey

Lowe

Schwartz

Melnick

Thompson

CB.

Induction of sarcomas by mutant IDH2. Genes Dev. 2013 Sep 15;27(18):1986–98. doi:10.1101/gad.226753.113.

43.

Turcan

Rohle

Goenka

Walsh

Fang

Yilmaz

Campos

Fabius

Ward

Thompson

Kaufman

Guryanova

Levine

Heguy

Viale

Morris

Huse

Mellinghoff

Chan

TA.

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Feb 15;483(7390):479–83. doi:10.1038/nature10866.

44.

Turcan

Makarov

Taranda

Wang

Fabius

AWM

Zheng

El-Amine

Haddock

Nanjangud

LeKaye

Brennan

Cross

Huse

Kelleher

Osten

Thompson

Chan

TA.

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018 Jan;50(1):62–72. doi:10.1038/s41588-017-0001-z.

45.

Sasaki

Knobbe

Itsumi

Elia

Harris

Chio

Cairns

McCracken

Wakeham

Haight

Ten

Snow

Ueda

Inoue

Yamamoto

Rao

Yen

Mak

TW.

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012 Sep 15;26(18):2038–49. doi:10.1101/gad.198200.112.

46.

Modrek

Golub

Khan

Bready

Prado

Bowman

Deng

Zhang

Rocha

Raviram

Lazaris

Stafford

LeRoy

Kader

Dhaliwal

Bayin

Frenster

Serrano

Chiriboga

Baitalmal

Nanjangud

Chi

Golfinos

Wang

Karajannis

Bonneau

Reinberg

Tsirigos

Zagzag

Snuderl

Skok

Neubert

Placantonakis

DG.

Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2. Cell Rep. 2017 Oct 31;21(5):1267–80. doi:10.1016/j.celrep.2017.10.009.

47.

Bardella

Al-Dalahmah

Krell

Brazauskas

Al-Qahtani

Tomkova

Adam

Serres

Lockstone

Freeman-Mills

Pfeffer

Sibson

Goldin

Schuster-Boeckler

Pollard

Soga

McCullagh

Schofield

Mulholland

Ansorge

Kriaucionis

Ratcliffe

Szele

Tomlinson

Expression of Idh1(R132H) in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell. 2016 Oct 10;30(4):578–94. doi:10.1016/j.ccell.2016.08.017.

48.

Suijker

Baelde

Roelofs

Cleton-Jansen

Bovee

JV.

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Oncotarget. 2015 Jun 20;6(17):14832–42. doi:10.18632/oncotarget.4024.

49.

Saha

Parachoniak

Ghanta

Fitamant

Ross

Najem

Gurumurthy

Akbay

Sia

Cornella

Miltiadous

Walesky

Deshpande

Zhu

Hezel

Yen

Straley

Travins

Popovici-Muller

Gliser

Ferrone

Apte

Llovet

Wong

Ramaswamy

Bardeesy

Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 2014 Sep 4;513(7516):110–4. doi:10.1038/nature13441.

50.

Sasaki

Knobbe

Munger

Lind

Brenner

Brustle

Harris

Holmes

Wakeham

Haight

You-Ten

Schalm

Virtanen

Reifenberger

Ohashi

Barber

Figueroa

Melnick

Zuniga-Pflucker

Mak

TW.

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012 Aug 30;488(7413):656–9. doi:10.1038/nature11323.

51.

Yang

Zhao

Wakeham

Tseng

Leca

Berger

Saunders

Fortin

Gao

Yuan

Xiao

Zhang

Gao

Zhou

Wang

Mak

IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis. Blood. 2021 Feb 18;137(7):945–58. doi:10.1182/blood.2020007075.

52.

Ward

Kapoor

Rohle

Turcan

Abdel-Wahab

Edwards

Khanin

Figueroa

Melnick

Wellen

O’Rourke

Berger

Chan

Levine

Mellinghoff

Thompson

CB.

IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Feb 15;483(7390):474–8. doi:10.1038/nature10860.

53.

McKenney

Lau

Somasundara

AVH

Spitzer

Intlekofer

Ahn

Shank

Rapaport

Patel

Papalexi

Shih

Chiu

Freinkman

Akbay

Steadman

Nagaraja

Yen

Teruya-Feldstein

Wong

Rampal

Vander Heiden

Thompson

Levine

RL.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest. 2018 Feb 1;128(2):789–804. doi:10.1172/JCI94516.

54.

Wang

Morita

DiNardo

Furudate

Tanaka

Yan

Patel

MacBeth

Liu

Frattini

Matthews

Little

Gumbs

Song

Zhang

Thompson

Kadia

Garcia-Manero

Jabbour

Ravandi

Bhalla

Konopleva

Kantarjian

Andrew Futreal

Takahashi

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 May 10;12(1):2607. doi:10.1038/s41467-021-22874-x.

55.

Pusch

Krausert

Fischer

Balss

Ott

Schrimpf

Capper

Sahm

Eisel

Beck

Jugold

Eichwald

Kaulfuss

Panknin

Rehwinkel

Zimmermann

Hillig

Guenther

Toschi

Neuhaus

Haegebart

Hess-Stumpp

Bauser

Wick

Unterberg

Herold-Mende

Platten

von Deimling

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 2017 Apr;133(4):629–44. doi:10.1007/s00401-017-1677-y.

56.

Machida

Nakagawa

Matsunaga

Yamaguchi

Ogawara

Shima

Yamagata

Katsumoto

Hattori

Itoh

Seki

Nishiya

Nakamura

Suzuki

Imaoka

Baba

Suzuki

Sampetrean

Saya

Ichimura

Kitabayashi

A potent blood-brain barrier-permeable mutant IDH1 inhibitor suppresses the growth of glioblastoma with IDH1 mutation in a patient-derived orthotopic xenograft model. Mol Cancer Ther. 2020 Feb;19(2):375–83. doi:10.1158/1535-7163.MCT-18-1349.

57.

Yen

Travins

Wang

David

Artin

Straley

Padyana

Gross

DeLaBarre

Tobin

Chen

Nagaraja

Choe

Jin

Konteatis

Cianchetta

Saunders

Salituro

Quivoron

Opolon

Bawa

Saada

Paci

Broutin

Bernard

de Botton

Marteyn

Pilichowska

Fang

Jiang

Wei

Jin

Silverman

Liu

Yang

Dang

Dorsch

Penard-Lacronique

Biller

SM.

AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017 May;7(5):478–93. doi:10.1158/2159-8290.CD-16-1034.

58.

Kernytsky

Wang

Hansen

Schalm

Straley

Gliser

Yang

Travins

Murray

Dorsch

Agresta

Schenkein

Biller

Liu

Yen

KE.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015 Jan 8;125(2):296–303. doi:10.1182/blood-2013-10-533604.

59.

Chaturvedi

Herbst

Pusch

Klett

Goparaju

Stichel

Kaulfuss

Panknin

Zimmermann

Toschi

Neuhaus

Haegebarth

Rehwinkel

Hess-Stumpp

Bauser

Bochtler

Struys

Sharma

Bakkali

Geffers

Araujo-Cruz

Thol

Gabdoulline

Ganser

von Deimling

Rippe

Heuser

Kramer

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia. 2017 Oct;31(10):2020–8. doi:10.1038/leu.2017.46.

60.

Okoye-Okafor

Bartholdy

Cartier

Gao

Pietrak

Rendina

Rominger

Quinn

Smallwood

Wiggall

Reif

Schmidt

Zhao

Joberty

Faelth-Savitski

Bantscheff

Drewes

Duraiswami

Brady

Groy

Narayanagari

Antony-Debre

Mitchell

Wang

Kao

Christopeit

Carvajal

Barreyro

Paietta

Makishima

Will

Concha

Adams

Schwartz

McCabe

Maciejewski

Verma

Steidl

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nature Chem Biol. 2015 Nov;11(11):878–86. doi:10.1038/nchembio.1930.

61.

Tateishi

Wakimoto

Iafrate

Tanaka

Loebel

Lelic

Wiederschain

Bedel

Deng

Zhang

Shi

Gerszten

Zhang

Yeh

Curry

Zhao

Sundaram

Nigim

Koerner

MVA

Fisher

Roider

Kemeny

Samuels

Flaherty

Batchelor

Chi

Cahill

DP.

Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell. 2015 Dec 14;28(6):773–84. doi:10.1016/j.ccell.2015.11.006.

62.

Amatangelo

Quek

Shih

Stein

Roshal

David

Marteyn

Farnoud

de Botton

Bernard

Yen

Tallman

Papaemmanuil

Penard-Lacronique

Thakurta

Vyas

Levine

RL.

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017 Aug 10;130(6):732–41. doi:10.1182/blood-2017-04-779447.

63.

Quek

David

Kennedy

Metzner

Amatangelo

Shih

Stoilova

Quivoron

Heiblig

Willekens

Saada

Alsafadi

Vijayabaskar

Peniket

Bernard

Agresta

Yen

MacBeth

Stein

Vassiliou

Levine

De Botton

Thakurta

Penard-Lacronique

Vyas

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018 Aug;24(8):1167–77. doi:10.1038/s41591-018-0115-6.

64.

Aguado-Fraile

Tassinari

Ishii

Sigel

Lowery

Goyal

Gliser

Jiang

Pandya

Bardeesy

Choe

Deshpande

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol. 2021 Jun;17(16):2057–74. doi:10.2217/fon-2020-1274.

65.

Stahl

Tallman

MS.

Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019 Oct;187(2):157–62. doi:10.1111/bjh.16151.

66.

Norsworthy

Mulkey

Scott

Ward

Przepiorka

Charlab

Dorff

Deisseroth

Kazandjian

Sridhara

Beaver

Farrell

de Claro

Pazdur

Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin Cancer Res. 2020 Aug 15;26(16):4280–88. doi:10.1158/1078-0432.CCR-20-0834.

67.

Fathi

DiNardo

Kline

Kenvin

Gupta

Attar

Stein

de Botton

, Investigators ACS. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018 Aug 1;4(8):1106–10. doi:10.1001/jamaoncol.2017.4695.

68.

DiNardo

Jonas

Pullarkat

Thirman

Garcia

Wei

Konopleva

Dohner

Letai

Fenaux

Koller

Havelange

Leber

Esteve

Wang

Pejsa

Hajek

Porkka

Illes

Lavie

Lemoli

Yamamoto

Yoon

Jang

Yeh

Turgut

Hong

Zhou

Potluri

Pratz

KW.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617–29. doi:10.1056/NEJMoa2012971.

69.

Pollyea

Pratz

Letai

Jonas

Wei

Pullarkat

Konopleva

Thirman

Arellano

Becker

Chyla

Hong

Jiang

Potluri

DiNardo

CD.

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021 Feb 1;96(2):208–17. doi:10.1002/ajh.26039.

70.

DiNardo

Tiong

Quaglieri

MacRaild

Loghavi

Brown

Thijssen

Pomilio

Ivey

Salmon

Glytsou

Fleming

Zhang

Patel

Kornblau

Chua

Chen

Blombery

Flensburg

Cummings

Aifantis

Kantarjian

Huang

DCS

Roberts

Majewski

Konopleva

Wei

AH.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 Mar 12;135(11):791–803. doi:10.1182/blood.2019003988.

71.

Wei

Montesinos

Ivanov

DiNardo

Novak

Laribi

Kim

Stevens

Fiedler

Pagoni

Samoilova

Anagnostopoulos

Bergeron

Hou

Murthy

Yamauchi

McDonald

Chyla

Gopalakrishnan

Jiang

Mendes

Hayslip

Panayiotidis

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020 Jun 11;135(24):2137–45. doi:10.1182/blood.2020004856.

72.

Konopleva

Pollyea

Potluri

Chyla

Hogdal

Busman

McKeegan

Salem

Zhu

Ricker

Blum

DiNardo

Kadia

Dunbar

Kirby

Falotico

Leverson

Humerickhouse

Mabry

Stone

Kantarjian

Letai

Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016 Oct;6(10):1106–17. doi:10.1158/2159-8290.CD-16-0313.

73.

Sekeres

Guyatt

Abel

Alibhai

Altman

Buckstein

Choe

Desai

Erba

Hourigan

LeBlanc

Litzow

MacEachern

Michaelis

Mukherjee

O’Dwyer

Rosko

Stone

Agarwal

Colunga-Lozano

Chang

Hao

Brignardello-Petersen

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528–49. doi:10.1182/bloodadvances.2020001920.

74.

Al-Ali

Jaekel

Niederwieser

The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol. 2014 Jan;5(1):89–105. doi:10.1016/j.jgo.2013.08.004.

75.

Choe

Wang

DiNardo

Stein

de Botton

Roboz

Altman

Mims

Watts

Pollyea

Fathi

Tallman

Kantarjian

Stone

Quek

Konteatis

Dang

Nicolay

Nejad

Liu

Zhang

Liu

Goldwasser

Liu

Marks

Bowden

Biller

Attar

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 May 12;4(9):1894–905. doi:10.1182/bloodadvances.2020001503.

76.

Mitchell

Kennedy

Chen

McLeod

Ibrahimova

Arruda

Popescu

Gupta

Schimmer

Schuh

Yee

Bullinger

Herold

Gorlich

Buchner

Hiddemann

Berdel

Wormann

Cheok

Preudhomme

Dombret

Metzeler

Buske

Lowenberg

Valk

Zandstra

Minden

Dick

Wang

JC.

A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016 Dec 15;540(7633):433–7. doi:10.1038/nature20598.

77.

Lowery

Burris

III Janku

Shroff

Cleary

Azad

Goyal

Maher

Gore

Hollebecque

Beeram

Trent

Jiang

Fan

Aguado-Fraile

Choe

Gliser

Agresta

Pandya

Zhu

Abou-Alfa

GK.

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711–20. doi:10.1016/S2468-1253(19)30189-X.

78.

Intlekofer

Shih

Wang

Nazir

Rustenburg

Albanese

Patel

Famulare

Correa

Takemoto

Durani

Liu

Taylor

Farnoud

Papaemmanuil

Cross

Tallman

Arcila

Roshal

Petsko

Choe

Konteatis

Biller

Chodera

Thompson

Levine

Stein

EM.

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018 Jul;559(7712):125–9. doi:10.1038/s41586-018-0251-7.

79.

Harding

Lowery

Shih

Schvartzman

Hou

Famulare

Patel

Roshal

Zehir

You

Selcuklu

Viale

Tallman

Hyman

Reznik

Finley

LWS

Papaemmanuil

Tosolini

Frattini

MacBeth

Liu

Fan

Choe

Janjigian

Mellinghoff

Diaz

Levine

Abou-Alfa

Stein

Intlekofer

AM.

Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018 Dec;8(12):1540–7. doi:10.1158/2159-8290.CD-18-0877.

80.

Konteatis

Artin

Nicolay

Straley

Padyana

Jin

Chen

Narayaraswamy

Tong

Wang

Zhou

Cui

Cai

Luo

Fang

Tang

Nagaraja

Yang

Sui

Dang

Yen

Popovici-Muller

Codega

Campos

Mellinghoff

Biller

SA.

Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett. 2020 Feb 13;11(2):101–7. doi:10.1021/acsmedchemlett.9b00509.

81.

Chaturvedi

Goparaju

Gupta

Weder

Klunemann

Araujo Cruz

Kloos

Goerlich

Schottmann

Othman

Struys

Bahre

Grote-Koska

Brand

Ganser

Preller

Heuser

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia. 2020 Feb;34(2):416–26. doi:10.1038/s41375-019-0582-x.

82.

Molenaar

Botman

Smits

Hira

van Lith

Stap

Henneman

Khurshed

Lenting

Mul

Dimitrakopoulou

van Drunen

Hoebe

Radivoyevitch

Wilmink

Maciejewski

Vandertop

Leenders

Bleeker

van Noorden

CJ.

Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res. 2015 Nov 15;75(22):4790–802. doi:10.1158/0008-5472.CAN-14-3603.

83.

Molenaar

Radivoyevitch

Nagata

Khurshed

Przychodzen

Makishima

Bleeker

Wilmink

Carraway

Mukherjee

Sekeres

van Noorden

CJF

Maciejewski

JP.

IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin Cancer Res. 2018 Apr 1;24(7):1705–15. doi:10.1158/1078-0432.CCR-17-2796.

84.

Sulkowski

Corso

Robinson

Scanlon

Purshouse

Bai

Liu

Sundaram

Hegan

Fons

Breuer

Song

Mishra-Gorur

De Feyter

de Graaf

Surovtseva

Kachman

Halene

Gunel

Glazer

Bindra

RS.

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017 Feb 1;9(375):eaal2463. doi:10.1126/scitranslmed.aal2463.

85.

MacBeth

Chopra

Tang

Zheng

Avanzino

See

Schwickart

Figueroa

Quek

DiMartino

JF.

Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Exp Hematol. 2021 Jun;98:47–52.e6. doi:10.1016/j.exphem.2021.03.003.

86.

Chan

Thomas

Corces-Zimmerman

Xavy

Rastogi

Hong

Zhao

Medeiros

Tyvoll

Majeti

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015 Feb;21(2):178–84. doi:10.1038/nm.3788.

87.

Cathelin

Sharon

Subedi

Cojocari

Phillips

Leverson

MacBeth

Nicolay

Narayanaswamy

Ronseaux

Liu

Chan

SM.

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia. Epub 2021 Nov 6. doi:10.1038/s41375-021-01468-y.

88.

Boutzen

Saland

Larrue

de Toni

Gales

Castelli

Cathebas

Zaghdoudi

Stuani

Kaoma

Riscal

Yang

Hirsch

David

De Mas-Mansat

Delabesse

Vallar

Delhommeau

Jouanin

Ouerfelli

Le Cam

Linares

Junot

Portais

Vergez

Recher

Sarry

JE.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016 Apr 4;213(4):483–97. doi:10.1084/jem.20150736.

89.

Dutta

Zhang

Kohnke

Thomas

Linde

Gars

Stafford

Kaur

Nakauchi

Yin

Azizi

Narla

Majeti

Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. J Clin Invest. 2020 Apr 1;130(4):1843–9. doi:10.1172/JCI133344.

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy

Abstract

Keywords

Introduction

IDH1/2mt in Cancer Cell Stemness and Differentiation

Epigenetic Hypermethylation and Cellular Dedifferentiation in mtIDH1/2 Cells

Induction of Differentiation by mtIDH1/2 Inhibitors in Preclinical Models

Induction of Differentiation by mtIDH1/2 Inhibitors in Translational Studies

Induction of Differentiation by mtIDH1/2 Inhibitors in Patients

Resistance Mechanisms to mtIDH1/2 Inhibitors

Combination Therapies With mtIDH1/2 Inhibitors

Other Differentiation Strategies Directly or Indirectly Targeting mtIDH1/2

Concluding Remarks and Future Perspectives

Footnotes

Competing interest

Author Contributions

Funding

References